Editas Medicine, Inc.
Public company- Headquarters
- CAMBRIDGE, Massachusetts
- Industry
- Biotechnology
- Ticker
- EDIT
- CIK
- 0001650664
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| member of the Board of DirectorsElliott Levy, M.D. | Aug 5, 2026 | Departed |
| independent directorPatrick Ellinor, M.D., Ph.D. | Aug 5, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- Eloxx Pharmaceuticals, Inc.
director appointed: Geno J. Germano
- Voyager Therapeutics, Inc.
president appointed: Robin Swartz
- TScan Therapeutics, Inc.
Director departs: Garry Nicholson
- Moderna, Inc.
COO appointed: Juan Andres
- Executive departure
member of the Board of Directors departs: Elliott Levy, M.D.
Elliott Levy, M.D., member of the Board of Directors of Editas Medicine, Inc., resigns the role, effective August 4, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 5, 2026Role: member of the Board of Directors
- Executive appointment
independent director appointed: Patrick Ellinor, M.D., Ph.D.
Patrick Ellinor, M.D., Ph.D. was named independent director of Editas Medicine, Inc., effective August 6, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 5, 2026Role: independent director
Last verified Nov 8, 2026